Sarepta Therapeutics, Inc. (BMV:SRPT)
Mexico · Delayed Price · Currency is MXN | Market Cap | 31.08B -56.1% |
| Revenue (ttm) | 39.38B -2.2% |
| Net Income | 1.17B |
| EPS | 11.50 |
| Shares Out | n/a |
| PE Ratio | 26.50 |
| Forward PE | 7.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 2,754 |
| Open | 399.20 |
| Previous Close | 399.20 |
| Day's Range | 399.20 - 399.20 |
| 52-Week Range | 198.74 - 818.65 |
| Beta | n/a |
| RSI | 53.24 |
| Earnings Date | May 6, 2026 |
About Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; ... [Read more]
News
Sarepta price target lowered to $19 from $20 at Evercore ISI
Evercore ISI lowered the firm’s price target on Sarepta (SRPT) to $19 from $20 and keeps an In Line rating on the shares.
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi...
Sarepta reports Q1 adjusted EPS $3.16 vs ($3.42) last year
Reports Q1 revenue $730.8M, consensus $475.01M. “We entered 2026 with clear priorities-stabilizing the business, restoring growth, maintaining financial strength, and advancing a pipeline that we beli...
Sarepta Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw stabilized operations, strong cash reserves, and positive operating profit, with ELEVIDYS and PMO franchises performing steadily. Promising siRNA pipeline data and expanded commercial initiatives support full-year guidance of $1.2–$1.4 billion.
Sarepta Therapeutics Quarterly report: Q1 2026
Sarepta Therapeutics has published its Q1 2026 quarterly earnings report on May 6, 2026.
Sarepta Therapeutics Earnings release: Q1 2026
Sarepta Therapeutics released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Sarepta Therapeutics Slides: Q1 2026
Sarepta Therapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2026. "W...
Sarepta Therapeutics Proxy statement: Proxy filing
Sarepta Therapeutics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasd...
Roche decision could hurt Sarepta in U.S., says H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor reiterates a Sell rating on Sarepta (SRPT) with a $5 price target saying Roche’s (RHHBY) new placebo-controlled Phase 3 study raises the risk that Elevidys…
Sarepta price target raised to $19 from $18 at RBC Capital
RBC Capital raised the firm’s price target on Sarepta (SRPT) to $19 from $18 and keeps a Sector Perform rating on the shares as part of the firm’s broader research…
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2026 that were previously ap...
Deutsche ups Sarepta target, says 35% stock rally overdone
Deutsche Bank raised the firm’s price target on Sarepta (SRPT) to $14 from $12 and keeps a Sell rating on the shares. The company yesterday exported positive preliminary data for…
Sarepta price target raised to $35 from $29 at Wedbush
Wedbush raised the firm’s price target on Sarepta (SRPT) to $35 from $29 and keeps an Outperform rating on the shares after including SRP-1001 for facioscapulohumeral muscular dystrophy and SRP-1003…
Sarepta price target raised to $13 from $9 at Citi
Citi analyst Yigal Nochomovitz raised the firm’s price target on Sarepta (SRPT) to $13 from $9 and keeps a Sell rating on the shares. The firm says yesterday’s “positive” Phase…
Sarepta price target raised to $25 from $20 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Sarepta (SRPT) to $25 from $20 and keeps an Equal Weight rating on the shares. Early Phase 1/2 data in facioscapulohumeral muscular…
Sarepta initial siRNA data ‘thin and somewhat mixed,’ says Leerink
After Sarepta (SRPT) Therapeutics shared the first clinical results from two of its siRNA programs for neuromuscular diseases, Leerink analyst Joseph Schwartz said the initial siRNA data in DM1 and…
Sarepta early DM1 data ‘appear promising,’ says Oppenheimer
Oppenheimer analyst Kostas Biliouris says Sarepta’s (SRPT) myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy data “appear promising.” However, the early nature of data and use of di...
Sarepta Therapeutics Transcript: Study result
Preliminary phase I/II data for SRP-1001 (FSHD) and SRP-1003 (DM1) show robust, dose-dependent muscle delivery, strong gene knockdown, and favorable safety profiles. Both programs plan to advance to phase III in 2027, with more MAD data expected later this year.
Sarepta Therapeutics Press release: Study result
Sarepta Therapeutics issued a press release on March 25, 2026, disclosing material business information to investors.
Sarepta Therapeutics Slides: Study result
Sarepta Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 25, 2026.
Sarepta announces first clinical data from pipeline targeting FSHD1, DM1
Sarepta (SRPT) Therapeutics shared the first clinical results from two of its siRNA programs for neuromuscular diseases. Early results from Phase 1/2 ascending dose studies of SRP-1001 for facioscapul...
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared the first clinical results from two of its siRNA p...
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wed., March 25, 2026, at 8:30 am Easter...